The capital markets day will include presentations describing an overview of the scientific foundation of RMC-035, the primary drug development program in acute kidney injury following cardiac surgery and clinical strategy in kidney transplantation. Market considerations and future pricing/reimbursement opportunities will also be discussed.

The capital markets day will feature a presentation from Professor Alexander Zarbock, M.D., from the Münster University Hospital, Germany.

To register for the event online please use the following link: http://enews.penser.se/public/event/RegistrationForm/43425B407942405D407740 (a link to the actual meeting will be sent out via email closer to September 21st)
To register for participation in person and for lunch please use the following link: http://enews.penser.se/public/event/RegistrationForm/43425B4076494B5D467840  

Agenda for Guard Therapeutic’s capital markets day

Registration and light lunch at Erik Penser Bank (Apelbergsgatan 27, Stockholm): 12:00 – 1.00 p.m. (CET).

The live stream will commence at 1:00 p.m. (CET)

• Opening statement
• Acute kidney injury in cardiac surgery – an intensive care physician’s perspective
  Professor Alexander Zarbock, MD, Director of Intensive Care at Münster University Hospital
• RMC-035 – a novel first-in-class investigational drug
  Peter Gilmour, PhD, Head of Preclinical Science, Guard Therapeutics 
• Clinical experience with RMC-035 – an overview of Phase 1 studies & detailed overview of the Phase 2 AKITA study in cardiac surgery
  Dr Michael Reusch, Chief Medical Officer, Guard Therapeutics 

Coffee break 2:30-2:45 p.m. (CET)

• Clinical strategy for RMC-035 in kidney transplantation
  Dr Michael Reusch, Chief Medical Officer, Guard Therapeutics 
• Market considerations & future pricing/reimbursement opportunities
  Dr Tobias L. Agervald, Chief Executive Officer, Guard Therapeutics
• Summary and closing statement

A live question and answer session will follow the summary 3:30-4:00 p.m. (CET)

Professor Alexander Zarbock, M.D., is a globally recognized expert and Key Opinion Leader (KOL) in the field of acute kidney injury. Professor Zarbock is Director of Anesthesiology, Operative Intensive Care and Pain Therapy at the University of Münster, Germany. His research interests cover a variety of aspects of intensive care and emergency medicine with a main focus on acute kidney injury, sepsis and organ protection. He is the author of over 150 scientific articles and book chapters in this field.